Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Payables (2019 - 2025)

Silence Therapeutics (SLN) has disclosed Payables for 7 consecutive years, with $13.4 million as the latest value for Q4 2025.

  • Quarterly Payables fell 18.56% to $13.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.4 million through Dec 2025, down 18.56% year-over-year, with the annual reading at $13.4 million for FY2025, 18.56% down from the prior year.
  • Payables hit $13.4 million in Q4 2025 for Silence Therapeutics, down from $17.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $18.8 million in Q1 2025 to a low of $13.4 million in Q4 2025.
  • Historically, Payables has averaged $15.6 million across 5 years, with a median of $15.1 million in 2023.
  • Biggest five-year swings in Payables: skyrocketed 34.38% in 2021 and later dropped 18.56% in 2025.
  • Year by year, Payables stood at $14.5 million in 2021, then grew by 1.94% to $14.8 million in 2022, then increased by 4.11% to $15.4 million in 2023, then increased by 6.31% to $16.4 million in 2024, then decreased by 18.56% to $13.4 million in 2025.
  • Business Quant data shows Payables for SLN at $13.4 million in Q4 2025, $17.0 million in Q3 2025, and $14.3 million in Q2 2025.